ViewRay

ViewRay, Inc. designs, manufactures and markets magnetic resonance imaging (MRI) system. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option—MRIdian SMART DENVER , Sept. 7, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company's MRIdian MRI-Guided Radiation Therapy System has received approval from the Chinese regulatory authority National Medical Products Administration (NMPA), allowing for its sale and utilization throughout China.

ViewRay Announces China NMPA Approval of its MRIdian® MRI-Guided Radiation Therapy for Cancer Patients

This is the First Hospital in Texas and the Third VA Hospital to Offer MRIdian® MRI-guided Radiation Therapy Cancer Treatment. DENVER , Aug. 23, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the VA Houston Healthcare System has selected a MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Michael E.

VA Houston Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services

Largest Cancer Center in Japan Enhances its Real-Time Soft-Tissue Tracking and On-Table Adaptive Delivery with MRIdian System CLEVELAND, Aug. 11, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the National Cancer Center Hospital (NCCH) of Japan has upgraded its original Cobalt MRIdian® MRI-Guided Radiation Therapy System to the MRIdian Linac System and has treated its first patients. The MRIdian system will enable National Cancer Center Hospital to offer advanced MRI-guided radiation therapy technology to cancer patients who are seeking personalized treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.

National Cancer Center Hospital in Tokyo Upgrades to MRIdian® Linac for MRI-Guided Radiation Therapy and has treated its first patients

Innovative cancer therapy company to leverage Colorado bioscience talent resources DENVER , Aug. 8, 2022 /PRNewswire/ -- ViewRay, Inc . (Nasdaq: VRAY), a medical device company that designs, manufactures, and markets the MRIdian® radiation therapy system, announced today that it is moving its headquarters to Denver, Colorado as it continues to attract top-tier talent from the state's growing medical technology sector.

ViewRay Selects Denver for Headquarters

ViewRay, Inc. (NASDAQ:VRAY ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Matt Harrison - Director, IR Scott Drake - President & CEO Zach Stassen - CFO Conference Call Participants Rick Wise - Stifel Sam Eiber - LDR Jason Bednar - Piper Sandler Calvin Chu - Morgan Stanley Mike Ott - Oppenheimer Operator Good day. My name is Melanie, and I will be your conference operator today.

ViewRay, Inc. (VRAY) CEO Scott Drake on Q2 2022 Results - Earnings Call Transcript

ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 13.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates

Multiyear campaign will highlight clinical evidence and patient impact of MRIdian for cancer treatment CLEVELAND , Aug. 2, 2022 /PRNewswire/ -- ViewRay, Inc, the U.S. maker of the MRIdian System, today announced a partnership with award-winning journalist and cancer advocate Katie Couric's multi-media company, Katie Couric Media ("KCM"). ViewRay and KCM are working together to launch a national awareness campaign to educate patients and clinicians about MRIdian SMART (Stereotactic MRI-guided adaptive radiotherapy) for treatment of pancreatic, prostate, lung, liver, breast, colorectal and oligometastatic cancers.

ViewRay and Katie Couric Media Partner to Raise Awareness about MRIdian® MRI-Guided Radiation Therapy

CLEVELAND , Aug. 2, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights Total revenue for the second quarter 2022 was approximately $22.1 million, primarily from three revenue units and one upgrade, compared to approximately $15.0 million, primarily from two revenue units, in the second quarter of 2021.

ViewRay Announces Second Quarter 2022 Results

Represents the first in Lille, France to Bring the Benefits of Precision Radiation Therapy to the Hauts de France Region CLEVELAND , July 29, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Centre Oscar Lambret has selected a MRIdian MRI-Guided Radiation Therapy System. The center will be the first in Lille, France to offer advanced MRI-guided radiation therapy technology in the Hauts de France region.

Centre Oscar Lambret Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System

CLEVELAND , July 19, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2022 financial results. ViewRay will hold a conference call to discuss results on Tuesday, August 2, 2022 at 4:30 p.m.

ViewRay Announces Conference Call for Second Quarter 2022 Financial Results to be Held After Market on August 2, 2022

Represents Second VA Hospital to Offer MRIdian MRI-guided Radiation Therapy Cancer Treatment Directly to Veterans CLEVELAND , June 9, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the VA Ann Arbor Healthcare System (VAAAHS) has selected a MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Lieutenant Colonel Charles S. Kettles VA Medical Center.

VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services

CLEVELAND , June 7, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Shin-Matsudo Central General Hospital has purchased a MRIdian MRI-guided radiation therapy system for installation at Shin-Matsudo Accuracy Radiation Therapy (SMART) Center in Japan. This is the third MRIdian system in Japan intended to help address an unmet need with a growing population and an increasing rate of cancer patients in Toukatsu.

Shin-Matsudo Central General Hospital Select's ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Expand Access to Precision Radiation Therapy

ViewRay (VRAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes ViewRay (VRAY) a New Buy Stock

Retrospective analysis shows MRIdian's small treatment margins enabled by adaptation and real-time tracking and automated beam control may allow for ablative radiation with minimal toxicity in hard to treat lung lesions CLEVELAND , May 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today the results of a study presented at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) titled, "MR-guided SBRT/Hypofractionated RT for Metastatic and Primary Ultracentral and Central Lung Lesions," which demonstrated that the real-time image-guidance, small treatment margins and adaptation afforded by MRIdian SMART (Stereotactic MRI-Guided Adaptive Radiotherapy) may allow for ablative radiation with minimal toxicity in ultracentral/central lung lesions. Prior studies of stereotactic body radiation therapy (SBRT) for ultracentral and central lung lesions have reported high rates of toxicity, including reports of fatal Grade 5 toxicities.

Clinical Value of MRIdian® MRI-Guided Radiation Therapy in the Treatment of Ultracentral/Central Lung Tumors Presented at ESTRO 2022

ViewRay, Inc. (NASDAQ:VRAY ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Matt Harrison - Director, Investor Relations Scott Drake - President and CEO Zach Stassen - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler Frank Pinal - Jefferies Justin Walsh - B. Riley Securities Sam Eiber - BTIG Mike Ott - Oppenheimer Operator Thank you for standing by.

ViewRay, Inc.'s (VRAY) CEO Scott Drake on Q1 2022 Results - Earnings Call Transcript

ViewRay celebrates 10-years as the first and only company to offer real-time tissue tracking with automatic beam gating and will host a lunch symposium highlighting new MRIdian A3i features   CLEVELAND , May 6, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO), with nearly 40 presentations and posters highlighting MRIdian clinical and research experience. This year's ESTRO meeting will be held May 6-10, 2022 online and in-person in Copenhagen, Denmark.

MRIdian Clinical and Research Experience Featured in Nearly 40 Abstracts at ESTRO 2022, the Leading European Radiation Oncology Meeting

ViewRay (VRAY) delivered earnings and revenue surprises of 12.50% and 13.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Reports Q1 Loss, Tops Revenue Estimates

CLEVELAND , May 5, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights Total revenue for the first quarter 2022 was approximately $18.9 million, primarily from three revenue units, compared to approximately $15.5 million, primarily from two revenue units, in the first quarter of 2021.

ViewRay Announces First Quarter 2022 Results

MRIdian will be the First MRI-Guided Radiation Therapy System at the UCI Chao Family Comprehensive Cancer Center facility opening in late 2023 CLEVELAND , May 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that UCI Health has purchased a MRIdian MRI-guided radiation therapy system for its new Chao Family Comprehensive Cancer Center and Ambulatory Care and will soon be offering advanced ViewRay MRIdian SMART MRI-guided radiation therapy. UCI Health is the clinical enterprise of the University of California, Irvine.

UCI Health Adopts ViewRay® MRIdian® MRI-Guided Radiation Therapy System

CLEVELAND, April 21, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2022 financial results. ViewRay will hold a conference call to discuss results on Thursday, May 5, 2022 at 4:30 p.m.

ViewRay Announces Conference Call for First Quarter 2022 Financial Results to be Held After Market on May 5, 2022

Center Becomes First MRIdian Program in Southern Europe to Reach this Treatment Milestone CLEVELAND, March 15, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that University Hospital Agostino Gemelli has surpassed the treatment of 1,000 patients using the MRIdian® MRI-guided radiation therapy system. University Hospital Agostino Gemelli is the fifth MRIdian center to reach this treatment milestone in bringing the benefits of MRI-guided radiation therapy to cancer patients.

University Hospital Agostino Gemelli Treats its 1,000th Patient Using MRIdian® MRI-Guided Radiation Therapy

CLEVELAND, March 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Wednesday, March 16, 2022. The event will begin at 4:00 pm ET.

ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on March 16, 2022

CLEVELAND, March 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced the first toxicity results from the prospective single-arm Phase II SCIMITAR trial. A secondary analysis compared the findings of treatment under CT-guidance to MRI-guidance and found that patients treated with MRI-guidance had a 30.5 percent reduction in any grade acute GI toxicity and a 32 percent reduction in any grade cumulative GI toxicity up to 6 months.

First Toxicity Results from SCIMITAR Prospective Phase II Trial Signal Favorable Toxicity Profile of Post-Prostatectomy Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer

CLEVELAND, March 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Acibadem Group, one of the leading private healthcare service institutions in Turkey, has purchased a second MRIdian MRI-guided radiation therapy system for installation at the Acibadem Altunizade Hospital in Istanbul, Turkey. Renowned for its desire to invest in cutting edge technologies, Acibadem Group began treatments with its first MRIdian system at Acibadem Maslak Hospital in September 2018, marking the first MRI-guided radiotherapy treatments in Turkey.

Acibadem Group Purchases Second MRIdian® System for Acibadem Altunizade Hospital in Istanbul

ViewRay, Inc. (VRAY) CEO Scott Drake on Q4 2021 Results - Earnings Call Transcript

News for ViewRay Stock (VRAY)